FR09C0037I2 - Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise - Google Patents

Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Info

Publication number
FR09C0037I2
FR09C0037I2 FR09C0037C FR09C0037C FR09C0037I2 FR 09C0037 I2 FR09C0037 I2 FR 09C0037I2 FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 C FR09C0037 C FR 09C0037C FR 09C0037 I2 FR09C0037 I2 FR 09C0037I2
Authority
FR
France
Prior art keywords
japanese encephalitis
attenuated
vero cell
vaccine
encephalitis virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR09C0037C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Corp
Walter Reed Army Institute of Research
Original Assignee
CJ Corp
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp, Walter Reed Army Institute of Research filed Critical CJ Corp
Publication of FR09C0037I1 publication Critical patent/FR09C0037I1/fr
Application granted granted Critical
Publication of FR09C0037I2 publication Critical patent/FR09C0037I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR09C0037C 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise Active FR09C0037I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR19970042001 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
FR09C0037I1 FR09C0037I1 (US06559137-20030506-C00021.png) 2009-09-25
FR09C0037I2 true FR09C0037I2 (fr) 2021-11-05

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
FR09C0037C Active FR09C0037I2 (fr) 1997-08-28 2009-08-14 Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise

Country Status (15)

Country Link
US (1) US6309650B1 (US06559137-20030506-C00021.png)
EP (2) EP1025209B1 (US06559137-20030506-C00021.png)
JP (1) JP4161017B2 (US06559137-20030506-C00021.png)
KR (1) KR100314404B1 (US06559137-20030506-C00021.png)
CN (1) CN1142271C (US06559137-20030506-C00021.png)
AU (1) AU748730B2 (US06559137-20030506-C00021.png)
CA (1) CA2301000C (US06559137-20030506-C00021.png)
DE (2) DE122009000037I2 (US06559137-20030506-C00021.png)
DK (2) DK1025209T3 (US06559137-20030506-C00021.png)
ES (2) ES2281929T3 (US06559137-20030506-C00021.png)
FR (1) FR09C0037I2 (US06559137-20030506-C00021.png)
MY (1) MY129773A (US06559137-20030506-C00021.png)
NL (1) NL300391I2 (US06559137-20030506-C00021.png)
NZ (1) NZ503522A (US06559137-20030506-C00021.png)
WO (1) WO1999011762A1 (US06559137-20030506-C00021.png)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
JP4371343B2 (ja) * 1998-10-05 2009-11-25 財団法人阪大微生物病研究会 日本脳炎ウイルス群感染症に対する不活化ワクチンのための増強免疫原およびその製造方法
DK1183332T3 (da) * 1999-04-22 2010-09-06 Us Agriculture Porcint Reproduktions- og Respirations Syndrom-vaccine baseret på isolere JA-142
WO2001076624A1 (fr) * 2000-04-07 2001-10-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccin inactive contre l'encephalite japonaise b et procede d'elaboration associe
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
MY173418A (en) * 2007-12-26 2020-01-23 Daiichi Sankyo Co Ltd Method of producing japanese encephalitis avccines stably storable over long time and use of the vaccine
WO2009147980A1 (ja) * 2008-06-04 2009-12-10 財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
JP5744517B2 (ja) * 2008-07-30 2015-07-08 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
DK3785730T3 (da) 2011-12-06 2024-05-06 Valneva Austria Gmbh Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner
AU2014338520B2 (en) * 2013-09-14 2019-12-05 Bharat Biotech International Limited A viral vaccine and methods of manufacture thereof
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
EP3393509B1 (en) 2015-12-23 2024-02-28 Valneva SE Virus purification
CN108697786B (zh) * 2016-01-15 2022-05-27 Km生物医药股份公司 含有固定化病毒粒子的疫苗
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
EP3684404A1 (en) 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
AU2018359556B2 (en) 2017-11-03 2021-12-02 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR20200094191A (ko) 2017-11-30 2020-08-06 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
JP7376013B2 (ja) * 2018-08-27 2023-11-08 マイキャン・テクノロジーズ株式会社 不死化単球細胞および誘導細胞を用いた抗感染症薬，ワクチンなどの評価方法
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
CA2301000A1 (en) 1999-03-11
EP1025209B1 (en) 2007-02-28
DE69837211T2 (de) 2007-12-06
ES2281929T3 (es) 2007-10-01
EP1604685B1 (en) 2012-02-22
EP1604685A2 (en) 2005-12-14
DE122009000037I1 (de) 2009-11-05
AU748730B2 (en) 2002-06-13
JP2001514844A (ja) 2001-09-18
DE69837211D1 (de) 2007-04-12
NZ503522A (en) 2001-06-29
FR09C0037I1 (US06559137-20030506-C00021.png) 2009-09-25
CN1142271C (zh) 2004-03-17
AU9004798A (en) 1999-03-22
DE122009000037I2 (de) 2011-06-16
CN1272879A (zh) 2000-11-08
NL300391I1 (nl) 2009-08-03
WO1999011762A1 (en) 1999-03-11
US6309650B1 (en) 2001-10-30
DK1025209T3 (da) 2007-06-25
KR100314404B1 (ko) 2002-10-12
NL300391I2 (nl) 2009-11-02
KR19990023955A (ko) 1999-03-25
MY129773A (en) 2007-04-30
DK1604685T3 (da) 2012-06-18
CA2301000C (en) 2003-07-08
EP1025209A1 (en) 2000-08-09
ES2382946T3 (es) 2012-06-14
EP1604685A3 (en) 2006-07-05
JP4161017B2 (ja) 2008-10-08

Similar Documents

Publication Publication Date Title
FR09C0037I2 (fr) Virus de l'encephalite japonaise attenue, adapte a des cellules vero et vaccin contre l'encephalite japonaise
GB2337755B (en) Virus vaccine
PL324906A1 (en) Vaccines against viral hepatitis of c type
PL321966A1 (en) Vaccine against viral hepatitis of b type
EP1112091A4 (en) FAST DEEP TEMPERATURE PRESSURE STERILIZATION AND VACCINE PRODUCTION
HUP0003911A3 (en) Treatment of neoplasms with viruses
IL147969A0 (en) Peptides that block viral infectivity and methods of use thereof
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
NZ310055A (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
HUP9904171A3 (en) Immunogenic peptides of foot-and-mouth disease viruses
AU4529401A (en) Aids ancestral viruses and vaccines
EP1113777A4 (en) NOVEL HEPATITIS C VIRUS PEPTIDES AND USES THEREOF
IL143149A0 (en) Stable, attenuated rabies virus mutants and live vaccines thereof
HK1034202A1 (en) Combined vaccine against hepatitis a and hepatitisb
GB9702990D0 (en) Virus vaccine
GB9423663D0 (en) Viral preparations, immunogens, and vaccines
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
AU8096998A (en) Attenuated human immunodeficiency virus vaccine
AU7276198A (en) Live virus vaccines to protect primates from hiv-1 infection and disease
GB9816773D0 (en) Virus vectors and expression elements,their preparation and use
GB9503395D0 (en) Viral,preparations,immunogens,and vaccines
EP1229042A4 (en) CYCLIC PEPTIDES AND AIDS VACCINES
AU6268199A (en) Live virus vaccines to protect primates from hiv-1 infection and disease
SI1073462T1 (sl) Kombinirano cepivo proti hepatitisu A in hepatitisu B